Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norio Seki

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Bioorganic & Medicinal Chemistry Letters|August 3, 2012
Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitorsJunji Miyata, Chiyoshi Kasahara, Toru Asano, et al.
Journal of Medicinal Chemistry|October 15, 2011
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitorFukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Bioorganic & Medicinal Chemistry Letters|August 3, 2012
Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitorsJunji Miyata, Chiyoshi Kasahara, Toru Asano, et al.
Journal of Medicinal Chemistry|October 15, 2011
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitorFukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, et al.
Pageof 3